anti-CD19-glucosteroid receptor modulator ADC ABBV-31
Term · Oncology and biomedicine · MLC-T-ONC-010282
An antibody drug conjugate (ADC) composed of an afucosylated immunoglobulin G1 (IgG1) monoclonal antibody directed against the B-cell-specific membrane protein CD19 conjugated to a glucocorticoid receptor (GR) modulator (GRM), with potential immunostimulating and antineoplastic activities. Upon administration, anti-CD19-GRM ADC ABBV-319 targets and binds to CD19. thereby inducing antibody-dependent cellular cytotoxicity (ADCC). Additionally, by delivering the GRM payload directly to CD19-expressing tumor cells, ABBV-319 inhibits the activation of GR-dependent expression of proliferative and anti-apoptotic genes. This induces apoptosis and inhibits tumor cell proliferation in CD19-expressing tumor cells. CD19 is a B-cell specific cell surface antigen overexpressed in B-cell lineage malignancies and drives B-cell proliferation. GRMs show robust anti-tumor activity against B-cell malignancies.
| Identifier | MLC-T-ONC-010282 |
|---|---|
| Field | Oncology and biomedicine |
| Synonyms | ADC ABBV-319; anti-CD19-GRM antibody-drug conjugate ABBV-319; anti-CD19-GRM ADC ABBV-319 |
| References | National Cancer Institute Thesaurus (CC BY 4.0) |
Record as JSON
{
"id": "MLC-T-ONC-010282",
"term": "anti-CD19-glucosteroid receptor modulator ADC ABBV-31",
"field": "Oncology and biomedicine",
"definition": "An antibody drug conjugate (ADC) composed of an afucosylated immunoglobulin G1 (IgG1) monoclonal antibody directed against the B-cell-specific membrane protein CD19 conjugated to a glucocorticoid receptor (GR) modulator (GRM), with potential immunostimulating and antineoplastic activities. Upon administration, anti-CD19-GRM ADC ABBV-319 targets and binds to CD19. thereby inducing antibody-dependent cellular cytotoxicity (ADCC). Additionally, by delivering the GRM payload directly to CD19-expressing tumor cells, ABBV-319 inhibits the activation of GR-dependent expression of proliferative and anti-apoptotic genes. This induces apoptosis and inhibits tumor cell proliferation in CD19-expressing tumor cells. CD19 is a B-cell specific cell surface antigen overexpressed in B-cell lineage malignancies and drives B-cell proliferation. GRMs show robust anti-tumor activity against B-cell malignancies.",
"synonyms": [
"ADC ABBV-319",
"anti-CD19-GRM antibody-drug conjugate ABBV-319",
"anti-CD19-GRM ADC ABBV-319"
],
"references": [
"National Cancer Institute Thesaurus"
],
"url": "https://mlchart.com/terminology/oncology/anti-cd19-glucosteroid-receptor-modulator-adc-abbv-31/"
}
Record 1,368 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.